Does RIPRETINIB Cause Product dose omission issue? 191 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 191 reports of Product dose omission issue have been filed in association with RIPRETINIB (QINLOCK). This represents 4.3% of all adverse event reports for RIPRETINIB.
191
Reports of Product dose omission issue with RIPRETINIB
4.3%
of all RIPRETINIB reports
2
Deaths
39
Hospitalizations
How Dangerous Is Product dose omission issue From RIPRETINIB?
Of the 191 reports, 2 (1.0%) resulted in death, 39 (20.4%) required hospitalization.
Is Product dose omission issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RIPRETINIB. However, 191 reports have been filed with the FAERS database.
What Other Side Effects Does RIPRETINIB Cause?
Fatigue (582)
Alopecia (517)
Extra dose administered (357)
Death (356)
Underdose (345)
Nausea (292)
Drug ineffective (291)
Disease progression (290)
Hospitalisation (280)
Neoplasm progression (263)
What Other Drugs Cause Product dose omission issue?
DUPILUMAB (18,189)
USTEKINUMAB (9,405)
GUSELKUMAB (9,267)
LENALIDOMIDE (8,145)
MEPOLIZUMAB (5,873)
TOFACITINIB (5,646)
VOXELOTOR (5,122)
BELIMUMAB (4,671)
SECUKINUMAB (4,572)
APREMILAST (4,460)
Which RIPRETINIB Alternatives Have Lower Product dose omission issue Risk?
RIPRETINIB vs RISANKIZUMAB
RIPRETINIB vs RISANKIZUMAB-RZAA
RIPRETINIB vs RISDIPLAM
RIPRETINIB vs RISEDRONATE
RIPRETINIB vs RISEDRONIC ACID